ApicHope(SZ:300723) Zheng Quan Ri Bao Zhi Sheng·2026-01-08 12:40Core Insights - The company emphasizes its focus on PROTAC and molecular glue technologies as key areas for future development and innovation [1] - The company has multiple PROTAC projects targeting diseases such as immunological disorders and tumors [1] Company Developments - The company has engaged in joint ventures and strategic investments to foster sustainable development and innovative products [1] - In May 2021, the company invested in a startup, Dandi Pharmaceutical, which specializes in the development of innovative drugs in the PROTAC field [1] - Dandi Pharmaceutical is developing an oral molecular glue drug, FD-001, for acute myeloid leukemia, multiple myeloma, and non-Hodgkin lymphoma, currently in Phase I clinical trials [1] Strategic Collaborations - The company participated in a new round of strategic financing for Dage Biotechnology, which focuses on the research, production, and sales of innovative protein degradation drugs [1] - Dage Biotechnology aims to develop new small molecule protein degraders targeting "undruggable" targets and has established research collaborations with Takeda and Merck [1]